Dr. Christian Wolf is a co-founder and managing partner of Lycalis s.p.r.l., a Belgian limited company established in 2009.
Over the past 20 years, Dr. Wolf held project and line management positions at global pharmaceutical companies. In these roles, he led numerous early and late-stage clinical development programmes in CNS indications to decision points. He has been a principal investigator or member of steering committees for many clinical studies in the field of neurology covering a range of technological platforms including small molecules, therapeutic proteins and antibodies.
Dr. Wolf's expertise comprises a range of CNS indications with most recent exposure to multiple sclerosis, epilepsy, and ischemic stroke. Additional activities in Alzheimer's disease, bipolar disorders, and movement disorders complement his profile as a CNS "all-rounder".
Dr. Wolf managed medical scientists and other development professionals in Europe and the US. Responsibilities included development activities for blockbuster drugs such as Keppra® or Betaferon®. His track record includes also interaction with major regulatory agencies (EMA, FDA, BfArM, MHRA) and collaborative projects with North American and Japanese corporations.
As a consultant, Dr. Wolf has been retained by North American and European companies including top-5, mid-sized and VC entities as well as by authorities such as the European Commission's Directorate General on Research, Technology and Development. The scope of services comprised strategic consultancy and interim management in clinical development for small and complex molecules in neurodegenerative and neuroinflammatory disorders. |
